Anne E. Huibers

Selecting Representative Tumour Bed Slices May Allow Reduced Embedding Without Loss of Accuracy in Response Evaluation to Neoadjuvant Immunotherapy in Stage IIIB/C Cutaneous Melanoma

Anders Bergström, Axel Nelson, Anne E. Huibers, Emel Cicek et autres

Background/Objectives: Histological assessment of the response to neoadjuvant immunotherapy in stage IIIB/C cutaneous melanoma is commonly performed using the INMC recommendations, which advocate embedding the entire tumour bed. However, this approach is highly resource-intensive. The original Swedish National Clinical Cancer Care Guidelines …

se (code pays fourni par la source)

Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis

A. Constantinescu, Roger Olofsson Bagge, Anne E. Huibers

Background Isolated limb perfusion (ILP) is a regional treatment for patients with melanoma in-transit metastases (ITM) confined to extremities. Reported complete response (CR) rates for ILP varies but is approximately 50–70 %. This study aims to analyze if specific immunological phenotypes could …

se (code pays fourni par la source)

Neoadjuvant immunotherapy for patients with resectable stage III cutaneous melanoma – a comparison between response in lymph node metastasis and in-transit metastasis

Ellen Krabbe, A. Nelson, Karl Björkström, Anne E. Huibers et autres

se, nl (code pays fourni par la source)

Management of liver metastases from uveal melanoma

Anne E. Huibers, Andrew W. Wong, Mark Christiaan Burgmans, Lars Ny et autres

Uveal melanoma is the most common primary intraocular malignancy in adults, with distinct genetic and clinical characteristics compared with cutaneous melanoma. Despite improvements in the treatment of the primary tumour, nearly half of the patients will develop distant metastases, most commonly in …

se, nl, us (code pays fourni par la source)

Neoadjuvant immunotherapy for patients with resectable melanoma

Axel Nelson, Ellen Krabbe, Karl Björkström, Anne E. Huibers et autres

Abstract Introduction Randomized clinical trials have shown that neoadjuvant immunotherapy leads to superior event-free survival (EFS) compared to adjuvant treatment in patients with resectable stage III/IV cutaneous melanoma. Although these results are encouraging, data from unselected real-world populations remain limited. Sweden was …

se, nl (code pays fourni par la source)

Magnetic seed localization in patients with nodal stage III melanoma and neoadjuvant immunotherapy, a feasibility study

Ellen Krabbe, Andrew W. Wong, Axel Nelson, Lars Ny et autres

Abstract Introduction Current guidelines for resectable macroscopic stage III melanoma recommend neoadjuvant immunotherapy and therapeutic lymph node dissection (TLND), followed by adjuvant treatment. However, the PRADO trial showed that TLND and adjuvant treatment could be omitted in patients with a major pathological …

se (code pays fourni par la source)

Percutaneous hepatic perfusion treatment for liver-dominant metastatic uveal melanoma: the updated experiences from the Scandinavian referral center

Andrew W. Wong, Anne E. Huibers, Roger Olofsson Bagge

Abstract Introduction Uveal melanoma has a high inclination to primarily metastasize to the liver. Percutaneous hepatic perfusion (PHP) is an effective, minimally invasive treatment that allows selective intrahepatic delivery of high dose melphalan while reducing systemic toxicity through hemofiltration of the hepatic …

se (code pays fourni par la source)

Can immunological phenotype predict response after isolated limb perfusion for patients with in-transit metastasis of melanoma?

A. Constantinescu, Roger Olofsson Bagge, Anne E. Huibers

Abstract Introduction Isolated limb perfusion (ILP) is a regional treatment for patients with melanoma in-transit metastases (ITM) confined to extremities, using a high dose of melphalan. ILP has a high response rate, with approximately 60% having a complete response (CR). This study …

se (code pays fourni par la source)

ASO Visual Abstract: Isolated Limb Infusion or Perfusion as First-Line Versus Second-Line Therapy for In-Transit Metastatic Melanoma

Michelle M. Dugan, Aleena Boby, Helana Ghali, Shaliz Aflatooni et autres

us, se (code pays fourni par la source)

ASO Visual Abstract: Isolated Limb Infusion/Perfusion for Unresectable Acral versus Non-Acral Melanoma In-Transit Metastases

Michelle M. Dugan, Jacob Samuel Israeli, Caitlyn Balsay-Patel, Anne E. Huibers et autres

us, se (code pays fourni par la source)

Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma – A Swedish retrospective real-world study (NEO-MEL)

Axel Nelson, Ellen Krabbe, Karl Björkström, Anne E. Huibers et autres

BACKGROUND: Recent clinical trials have demonstrated that neoadjuvant administration of PD-1 + /- CTLA-4 inhibitor is superior to adjuvant PD-1 inhibitors in patients with resectable stage III and IV cutaneous melanoma. However, the generalizability of these results to an unselected patient population …

se, nl (code pays fourni par la source)

Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis.

A. Constantinescu, Roger Olofsson Bagge, Anne E. Huibers

9565 Background: Isolated limb perfusion (ILP) is a regional treatment for patients with melanoma in-transit metastases (ITM) confined to extremities, using a high dose of melphalan. ILP has a high response rate, with approximately 60% having a complete response (CR). This study …

se (code pays fourni par la source)